Tobetsa mona ho bonts'a lifolakha tsa HAO leqepheng lena mme u lefelle katleho feela

Litaba tsa mohala

Ho Matlafatsa Litlhare Tsa Lisele Tsa Tlhaho ho Loantša Kankere

ngotsoeng ke mohlophisi

Isleworth Healthcare Acquisition Corp. le Cytovia Holdings, Inc. kajeno li phatlalalitse hore li kene tumellanong e tiileng ea ho kopanya khoebo. Ha ho phetheloa motsoako ona, Isleworth e tla bitsoa Cytovia Therapeutics, Inc. ("k'hamphani e kopantsoeng") le thepa ea eona e tloaelehileng le litokomane li lebeletsoe hore li lule li thathamisitsoe ho NASDAQ tlas'a matšoao a ticker INKC le INKCW, ka ho latellana.               

Khampani e kopaneng e tla tsoelapele ka ts'ebetso ea Cytovia mme e lule e tsepamisitse maikutlo ho nts'etsopele le ho etsa liforomo tsa tlatsetso tsa NK cell le NK engager antibody.

Khampani e kopantsoeng e tla tsamaisoa ke Dr. Daniel Teper, Co-Founder, Molula-setulo, le Mookameli ea ka Sehloohong oa Cytovia.

"Re leboha tšehetso e matla e tsoang ho bo-ramatsete ba bacha le ba seng ba ntse ba le teng le sehlopha sa bo-rakhoebo ba khale ba Isleworth. Re lebelletse hore ts'ebetso ena e potlakisa ts'ebetso ea pono ea Cytovia ea ho ntšetsa pele kalafo ea NK ho ea phekong ea mofets'e "ho boletse Dr. Teper. "Re khothatsoa ke lintlha tsa rona tsa preclinical tse sa tsoa hlahisoa ho AACR, tse tšehetsang tsoelo-pele ea lisele tsa rona tsa NK tse entsoeng ke iPSC (iNK) le Flex-NK™ cell engagers bakeng sa phekolo ea Hepatocellular Carcinoma." 

Bob Whitehead, CEO oa Isleworth, o itse: "Isleworth e hlahlobile lik'hamphani tse ngata tsa mahlale a bophelo mme e khahliloe haholo ke talenta le theknoloji e kopantsoeng ke Cytovia. Re lumela hore Cytovia ke e 'ngoe ea lik'hamphani tse tsoetseng pele ka ho fetisisa tsa kalafo ea lisele tse amehang ka nts'etsopele ea liphekolo tse ncha tsa mofetše. Liphekolo tsa lisele tsa oncology li se li tlisitse tšepo ho batho ba limilione. Mekhoa ea Cytovia e ka etsa hore mekhoa e ts'oanang e be bonolo haholoanyane 'ho tloha shelefong' le ho ba bonolo. ”

Mokhoa oa Phekolo oa Cytovia

Cytovia e ikemiselitse ho potlakisa phihlello ea mokuli ho liphekolo tsa phetoho ea lisele le li-immunotherapies, ho sebetsana le litlhoko tse ngata tse thata ka ho fetesisa tsa bongaka tse sa fihlelleheng ho oncology.

Khampani e tsepamisitse maikutlo ho sebeliseng sesole sa 'mele sa tlhaho ka ho theha liforomo tse tlatselletsang le tse sitisang tsa NK-cell le NK-engager antibody platforms. Ka ho khetheha, Cytovia e hlahisa mefuta e meraro ea lisele tsa iNK: lisele tsa iNK tse sa hlophisoang, lisele tsa TALEN® tse hlophisitsoeng ka liphatsa tsa lefutso tse nang le ts'ebetso e ntlafetseng le ho phehella, le lisele tsa TALEN® tse hlophisitsoeng ka liphatsa tsa lefutso tse nang le li-chimeric antigen receptors (CAR-iNKs) ho ntlafatsa tumor-specific. tebisitse. Theknoloji ea bobeli e tlatsetsang ea lejoe la sekhutlo ke sethala sa quadrivalent multispecific antibody se etselitsoeng ho kopanya lisele tsa NK ka ho lebisa NKp46 activating receptor ho sebelisa theknoloji ea Flex-NK™.

Li-platform tsena tse peli tsa theknoloji li ntse li sebelisoa ho nts'etsapele liphekolo tsa bakuli ba Hepatocellular Carcinoma (HCC) le lihlahala tse tiileng. Lithuto tsa bongaka li lebelletsoe ho qala bofelong ba 2022.

E thehiloe Aventura, FL, Cytovia e sebetsa lilaboratori tsa R & D Natick, MA le setsi sa tlhahiso ea lisele tsa cGMP Puerto Rico 'me e na le likamano tsa saense le Cellectis, CytoImmune Therapeutics, Univesithi ea Seheberu ea Jerusalema, INSERM, New York Stem Cell Foundation, National Cancer Institute, le Univesithi ea California San Francisco (UCSF). Cytovia Therapeutics e sa tsoa theha CytoLynx Therapeutics, tšebelisano ea maano e shebaneng le lipatlisiso le nts'etsopele, mesebetsi ea tlhahiso le khoebo ho Greater China le ho feta.

Pipeline ea Cytovia

Cytovia ke k'hamphani ea pele ea 'mele ea ho itšireletsa mafung e nang le bokhoni ba ho kopanya liphatsa tsa lefutso tsa NK Cell le Flex-NK™ cell engager antibody platforms ho hlahisa moloko o latelang oa immunotherapies bakeng sa lihlahala tsa mali le tse tiileng.

Potefolio ea Cytovia e kenyelletsa lipehelo le lipontšo tse nang le boemo bo leka-lekaneng ba kotsi.

GPC3 ke sepheo se ts'episang sa lihlahala tse tiileng, haholo-holo hepatocellular carcinoma, moo tlhoko ea bongaka e sa fihlellehang e leng ea bohlokoa haholo. Lenaneo le etelletseng pele la Cytovia le ikemiselitse ho theha liphekolo tsa boemo ba pele ba HCC tse tobane le GPC3. Bakhethoa ba bane ba pele ba lihlahisoa ba tla hlahlojoa e le kalafo e le 'ngoe hape e le liphekolo tse kopaneng. CYT-303, Cytovia's GPC3 Flex-NK™ engager, ke lesole la 'mele le ikhethileng le tlamang liseleng tsa hlahala tsa HCC ka GPC3 le ho NK liseleng ka NKp46 le CD16a. Bakeng sa bakuli ba nang le palo e fokolang kapa ts'ebetso ea lisele tsa NK, Cytovia e tla hlahloba ho eketsoa ha lisele tsa iNK, CYT-100, ho bula monyetla o feletseng oa leano lena la phekolo. Cytovia e boetse e nts'etsapele CYT-150, lisele tsa iNK tse hlophisitsoeng ka liphatsa tsa lefutso, ho ntlafatsa ho kenngoa ha hlahala le ho phehella ha lisele, tse ka 'nang tsa kopanngoa le CYT-303. Ho feta moo, CYT-503, GPC3-targeting CAR-iNK cell therapeutic, e etselitsoe ho ntlafatsa ho khetheha bakeng sa ho lebisa tumor. Cytovia e lebeletse ho kenya li-INDs bakeng sa CYT-303 le CYT-100, e lateloe ke INDs bakeng sa CYT-150 le CYT-503.

CD38 ke sepheo se thehiloeng hantle sa bongaka le khoebo bakeng sa Multiple Myeloma. Cytovia e ntse e hlahisa CYT-338 le CYT-538 tseo, ka ho latellana, li-CD38-targeting Flex-NK™ cell engagers le CAR-iNK cell bakeng sa phekolo ea Multiple Myeloma ho bakuli ba hlōlehileng ho phekola CD38 le li-agent tse lebisang ho B-cell maturation. antigen (BCMA).

Cytovia e boetse e nts'etsapele mokhethoa oa EGFR CAR iNK ea intracranial ho lebisa tlhokomelo ho wtEGFR le EGFR vIII ho sebetsana le tlhoko ea bohlokoa ea bongaka tsamaisong ea Glioblastoma multiforme e sa phekoleheng hona joale.

Cytovia e thehile litšebelisano le litsi tsa thuto le balekane ba indasteri ho kenyeletsoa Cellectis bakeng sa ho fetola liphatsa tsa lefutso tsa TALEN®. TALEN® ho fetola liphatsa tsa lefutso ke thekenoloji e qapiloeng le ho laoloa ke Cellectis, k'hamphani ea boemo bo holimo ea biotechnology e sebelisang sethala sa eona sa ho fetola liphatsa tsa lefutso ho nts'etsapele mekhoa e pholosang bophelo ea lisele le liphatsa tsa lefutso. Lipatente tsa TALEN® tsa liphatsa tsa lefutso tse laoloang ke Cellectis lefapheng la iNK le CAR-iNK li filoe tumello ho tloha Cellectis ke Cytovia 'me Cytovia e na le litokelo tsa nts'etsopele ea lefats'e le tsa khoebo ho litokelo tsena.

Melemo e Reriloeng le Tšebeliso ea Lichelete

Chelete e tsoang litsing tsa poraefete ("PIPE"), chelete e akhaonteng ea trust ea Isleworth (nete ea topollo), le chelete e tsoang ho lichelete tse ling tse lebelletsoeng, ka kakaretso ho fihlela ho lidolara tse limilione tse lekholo, li tla fa Cytovia chelete e kholo ho fihlela ho 2. lilemo tsa ho ntšetsa pele theknoloji ea eona e hlophisitsoeng ea iNK le Flex-NK™ cell engager. Cytovia e rera ho tsepamisa maikutlo linthong tse ngata tsa bohlokoa, ho kenyelletsa:

• Ho tlatsa li-IND tsa pele tse peli bakeng sa Flex-NK™ CYT-303 le iNK CYT-100

• Ho qala liteko tsa kliniki tsa Phase I/II ho lekola CYT-303 le CYT-100, e le 'ngoe le hammoho, bakeng sa kalafo ea HCC.

• Ho fumana le ho hlahisa lintlha tsa mantlha tsa kliniki bakeng sa CYT-303 le CYT-100 ho HCC

• Ho tlatsa INDs bakeng sa CYT-150 le CYT-503 le ho qala liteko tsa meriana tsa Phase I/II

• Ho tswelapele ho ntlafatsa dithekenoloji tsa iNK & Flex-NK™ le ho ntshetsapele diphaephe ka batho ba bangata ba kalafing.

Litaba Tse Amanang

Mabapi le mongoli

mohlophisi

Mohlophisi e moholo oa eTurboNew ke Linda Hohnholz. O lula ntlong e kholo ea eTN e Honolulu, Hawaii.

Leave a Comment

Arolelana ho...